Tumor Treating Fields Show Promise for Advanced Pancreatic Cancer
A fresh evaluation suggests that Tumor Treating Fields (TTFields) offer a modest benefit for patients with locally advanced pancreatic cancer, particularly in managing pain and improving quality of life. While not a cure, the therapy presents a potential new avenue for treatment in a disease with limited options.
Currently, no phase 3 clinical trials have demonstrated a benefit in overall survival with any treatment for inoperable, locally advanced pancreatic adenocarcinoma. However, after showing positive results in glioblastoma—where it has received CE marking and reimbursement in some regions—TTFields is now being studied for its effectiveness against other solid tumors.
According to research presented in recent findings, the international Panova-3 trial indicates TTFields may improve overall survival and provide pain relief for those with locally advanced pancreatic cancer.
Dr. Hélène Senellart (Institut de cancérologie de l’Ouest, réseau Unicancer) explained, “Les tumor treating fields ont un bénéfice modeste sur la survie, mais un intérêt vis-à-vis de la douleur et la qualité de vie dans l’adénocarcinome canalaire pancréatique localement avancé.”
TTFields are a non-invasive cancer therapy that utilizes low-intensity electric fields. These fields are delivered via electrodes placed on the skin, applying alternating electric fields of low intensity and intermediate frequencies (100-300 kHz) for a minimum of twenty hours a day using a portable device.
The therapy works by exerting physical forces on dividing cells, disrupting the mitotic spindle and inducing apoptosis—essentially inhibiting tumor proliferation. Researchers also believe this antimitotic effect may be complemented by immunologic modulation, which is currently under investigation.
Pancreatic cancer is a highly aggressive disease, with a median overall survival of less than six months in advanced, non-resectable cases, with adenocarcinoma accounting for approximately 90% of diagnoses, as noted here. Further research, including studies combining TTFields with chemotherapy, like gemcitabine and nab-paclitaxel, is ongoing to determine the full potential of this treatment approach, as detailed in this study.
